Is Fractalkine (CX3CL1) a master regulator of remyelination in MS?

Williams, Anna (Principal Investigator)

Status	Finished
Effective start/end date	1/10/16 → 30/09/19

Funding

UK-based charities: £253,524.00

1 Article

A systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis
Cunniffe, N., Vuong, K. A., Ainslie, D., Baker, D., Beveridge, J., Bickley, S. R. B., Camilleri, P., Craner, M., Fitzgerald, D. C., De La Fuente, A. G., Giovannoni, G., Gray, E., Hazlehurst, L., Kapoor, R., Kaur, R., Kozlowski, D., Lumicisi, B., Mahad, D., Neumann, B., Palmer, A., & 9 othersPeruzzotti-Jametti, L., Pluchino, S., Robertson, J., Rothaul, A., Shellard, L., Smith, K. J., Wilkins, A., Williams, A. C. & Coles, A. J., 12 Nov 2020, In: Journal of Neurology, Neurosurgery & Psychiatry.
Research output: Contribution to journal › Article › peer-review

Open Access
File